Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Eystein S Husebye, Frederik Castinetti, et al. 
Eur J Endocrinol. 2022 Oct 25;187(6):G1-G21. 
https://doi.org/10.1530/EJE-22-0689

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement
Margaret C S Boguszewski, Cesar L Boguszewski , et al. 
Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52. 
https://doi.org/10.1530/EJE-21-1186

Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop
John P Bilezikian 1, Aliya A Khan, et al. 
J Bone Miner Res. 2022 Nov;37(11):2293-2314. 
https://doi.org/10.1002/jbmr.4677